
“API niche kingpin at dirt-cheap multiples.”
No clear market view today
The signals we track (volume, delivery, price trend, deals, breadth and flows) aren't aligned for AARTIDRUGS today. That isn't bearish, just inconclusive.
50-day SMA is above 200-day SMA (bullish long-term trend)
India-specific risk checks.
Four fundamentals lenses on the company itself: valuation, growth, returns & margins, and financial health, judged against the stock's sector. A separate read from the Market Setup above.
Fairly valued
₹1,000 invested here buys about ₹49 of annual profit. A cheaper stock would buy more.
Steady growth
Moderate returns
Strong balance sheet
Data as of 18 Sept 2026, 11:10 am